BHBassem Habr

Bassem Habr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bassem Habr has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Evaluation of Amoxicillin–Clavulanate and Ertapenem in an Exploratory Rat Model of ESBL E. coli Peritonitis

    by Elie Haddad, Bassem Habr, Hussein Nassereddine, Nassim Fares

    Background: Extended-spectrum β-lactamase (ESBL)–producing Escherichia coli represent an increasing therapeutic challenge. While ertapenem (ERP) is commonly used as first-line therapy, amoxicillin–clavulanic acid (AMC) achieves therapeutic concentrations in serum and ascitic fluid and may offer a narrower-spectrum alternative. This exploratory preclinical study evaluated whether AMC produces effects comparable to ERP in a rat model of ESBL E. coli peritonitis. Methods: Thirty-three male rats were allocated to four groups: untreated E. coli, AMC, ERP, and sham controls. Peritonitis was induced by intraperitoneal injection of an ESBL-producing E. coli strain. The primary outcome was peritoneal bacterial culture positivity. Secondary outcomes included plasma inflammatory cytokines (CRP, PCT, TNF-α, IL-1β, IL-6), proteomic signaling markers, and histopathological inflammation scores in the peritoneum, spleen, and lungs. Results: One death occurred in the untreated group. Both AMC and ERP were associated with lower peritoneal culture positivity compared with untreated animals, with ERP achieving statistical significance and AMC showing a similar downward trend. Inflammatory cytokines and proteomic markers demonstrated comparable reductions in both treated groups. Histopathology showed reduced inflammatory scores, with AMC exhibiting the lowest peritoneal inflammation. Lung involvement was observed in 7/10 untreated rats versus 5/10 AMC- and ERP-treated rats; these differences were not statistically significant, reflecting the limited sample size. Conclusions: AMC and ERP produced broadly comparable effects on microbiological, biochemical, and inflammatory parameters in ESBL E. coli peritonitis. These findings suggest that AMC may merit further investigation as a potential narrower-spectrum option, though definitive comparisons require larger, adequately powered studies.

  • Open Access

    A New Breath: Dynamics of Respiratory Infections After the Lifting of Non-Pharmaceutical Interventions Related to COVID-19

    by Rouba Keyrouz, Bassem Habr, Marianne Antar Soutou, Sirine Abou Ismail, Marianne Abifadel, Josette Najjar-Pellet, Bernard Gerbaka, Elie Haddad

    The epidemiology of respiratory viruses shifted considerably following the COVID-19 pandemic and the subsequent rollback of non-pharmaceutical interventions (NPIs). The initial global containment strategies implemented during the SARS-CoV-2 outbreak profoundly altered viral transmission dynamics and circulation patterns. As the World Health Organization (WHO) declared COVID-19 no longer a public health emergency in May 2023, viral circulation began reverting to pre-pandemic trends. This retrospective observational study examined the evolving epidemiological patterns of respiratory infections during and after the lifting of NPI, assessing associated clinical manifestations and their relationship with patient-specific risk factors. Data were collected from 307 patients tested between October 2021 and December 2024 using a respiratory multiplex PCR at the Rodolphe Mérieux Laboratory in Lebanon. Results revealed a reemergence of pre-pandemic seasonal trends for most viruses. Rhinovirus remained the most prevalent pathogen, likely due to the absence of a vaccine. Respiratory syncytial virus (RSV) and Influenza A resumed their characteristic winter peaks, while human metapneumovirus (HMPV) showed no co-infections, suggesting viral interference. The persistence of Influenza A and SARS-CoV-2 appeared influenced by vaccine coverage, viral mutations, and environmental factors. Multiplex PCR testing proved to be a valuable yet costly tool for both diagnosis and epidemiological surveillance. Overall, this study highlights the importance of continued viral monitoring in the post-NPI period, reflecting both the effectiveness of NPIs in limiting viral spread and the importance of ensuring wider access to advanced diagnostic methods.


  • Open Access

    Stenotrophomonas maltophilia pneumonia in critical COVID-19 patients

    by Marc Raad, Marc Abou Haidar, Racha Ibrahim, Rouba Rahal, Jocelyne Abou Jaoude, Carine Harmouche, Bassem Habr, Eliane Ayoub, Gebrayel Saliba, Ghassan Sleilaty, et al.

    Stenotrophomonas maltophilia, an environmental aerobic non-fermentative Gram-negative bacilli, has gained attention in many nosocomial outbreaks. COVID-19 patients in intensive care unit have extended hospital stay and are severely immunosuppressed. This study aimed to determine the prevalence and risk factors of S.maltophilia pneumonia in critical COVID-19 patients. A total of 123 COVID-19 patients in ICU admitted between March 2020 and March 2021 were identified from the authors’ institutional database and assessed for nosocomial pneumonia. Demographic data and factors predisposing to S. maltophilia pneumonia were collected and analyzed. The mean age was 66 ± 13 years and 74% were males. Median APACHE and SOFA scores were 13 (IQR = 8–19) and 4 (3–6), respectively. The Median NEWS2 score was 6 (Q1 = 5; Q3 = 8). The Median ICU stay was 12 (Q1 = 7; Q3 = 22) days. S. maltophilia was found in 16.3% of pneumonia patients, leading to a lengthier hospital stay (34 vs. 20 days; p < 0.001). Risk factors for S. maltophilia pneumonia included previous treatment with meropenem (p < 0.01), thrombopenia (p = 0.034), endotracheal intubation (p < 0.001), foley catheter (p = 0.009) and central venous catheter insertion (p = 0.016). S.maltophilia nosocomial pneumonia is frequent in critical COVID-19 patients. Many significant risk factors should be addressed to reduce its prevalence and negative impact on outcomes.


  • Post‐transfusion platelet responses in critically ill cancer patients with hypoproliferative thrombocytopenia

    by Elodie Baron, Julien Charpentier, Anne François, Habib Ben Hadj Amor, Bassem Habr, Alain Cariou, Jean‐Daniel Chiche, Jean‐Paul Mira, Matthieu Jamme, Frédéric Pène

    BACKGROUND: Platelet transfusion is aimed at increasing platelet counts to prevent or treat bleeding. Critically ill cancer patients with hypoproliferative thrombocytopenia are high consumers of blood products. We herein described their post‐transfusion platelet responses in the intensive care unit (ICU) and analyzed the determinants of poor post‐transfusion increments.STUDY DESIGN AND METHODS: This was a single‐center 9‐year (2009‐2017) retrospective observational study. Patients with malignancies and presumed or proven hypoproliferative thrombocytopenia who had received at least one platelet transfusion in the ICU were included. Poor post‐transfusion platelet increments were defined as body surface‐adjusted corrected count increment (CCI) <7, or alternatively as weight‐adjusted platelet transfusion recovery (PTR) <0.2. Patients were deemed refractory to platelet transfusions when two consecutive ABO‐compatible transfusions resulted in poor platelet increments.RESULTS: A total of 1470 platelet transfusions received by 326 patients were analyzed. Indications for platelet transfusions were distributed into prophylactic (44.5%), peri‐procedural (18.1%) and therapeutic (37.4%). Regardless of indications, 54.6% and 55.4% of transfusion episodes were associated with a CCI <7 or a PTR <0.2. Factors independently associated with poor post‐transfusion increments were lower body mass index, spleen enlargement, concurrent severity of clinical condition, fever ≥39°C, antibiotic therapy and increased storage duration of platelet concentrates. Eventually, 48 patients developed refractoriness to platelet transfusion, which was associated increased incidence of bleeding events.CONCLUSION: Platelet transfusions are often associated with poor increments in critically ill cancer patients with hypoproliferative thrombocytopenia. The findings suggest amenable interventions to improve the platelet transfusion practices in this setting.